Ixekizumab, with or without concomitant methotrexate, improves signs and symptoms of PsA: week 52 results from Spirit-P1 and Spirit-P2 studies

BACKGROUND: The efficacy and safety of ixekizumab (IXE) with and without continuous concomitant methotrexate (MTX), for up to 52 weeks of treatment, were evaluated in patients with active psoriatic arthritis (PsA). METHODS: Patients with active PsA who were biologic-naive (SPIRIT-P1) or had prior in...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
izdano v:Arthritis Res Ther
Main Authors: Combe, Bernard, Tsai, Tsen-Fang, Huffstutter, J. Eugene, Sprabery, Aubrey Trevelin, Lin, Chen-Yen, Park, So Young, Kronbergs, Andris, Hufford, Matthew M., Nash, Peter
Format: Artigo
Jezik:Inglês
Izdano: BioMed Central 2021
Teme:
Research Article
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC7839215/
https://ncbi.nlm.nih.gov/pubmed/33499913
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s13075-020-02388-5
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki